Novo Nordisk: First Weight Loss Pill on the Verge of Approval

The market for obesity medications is undergoing a profound transformation. With the goal of making obesity treatment possible without injections in the future, Novo Nordisk has now applied to the US Food and Drug Administration (FDA) for approval of an oral version of its medication Wegovy. Notably, the decision to submit comes about two years after the publication of Phase 3 data, which was released in May 2023. According to company statements, the application was deliberately delayed as they initially wanted to focus on developing potentially...